Chronic Obstructive Pulmonary Disease Management and Outcomes

Chronic Obstructive Pulmonary Disease (COPD) is characterised by persistent airflow limitation, progressive breathlessness and systemic manifestations that together impose a substantial global health burden. Management hinges on the integration of pharmacological therapies—long-acting bronchodilators, inhaled corticosteroids and, in selected phenotypes, targeted biologics—with non-pharmacological measures such as smoking cessation, pulmonary rehabilitation, nutritional support and regular vaccination. Personalised care pathways aim to optimise inhaler technique, monitor exacerbation risk and address comorbidities including cardiovascular disease and osteoporosis. Early intervention strategies and multidisciplinary team approaches have been shown to slow decline in lung function, reduce healthcare utilisation and improve quality of life. Yet despite these advances, outcomes remain variable, underscoring the need for novel biomarkers and precision treatments to further refine prognostication and therapy.

Research from Nature Portfolio

Recent studies have harnessed large multi-ancestry datasets to delineate genetic determinants of lung function and COPD risk. Through genome-wide association analyses across diverse populations, over a thousand loci implicating hundreds of genes have been identified, elucidating pathways in airway remodelling, inflammation and epithelial repair. Genetic risk scores derived from these signals demonstrated robust prediction of COPD susceptibility across ancestry groups, and phenome-wide interrogation suggests potential repurposing of existing pharmacological agents targeting these pathways. These advances set the stage for functional genomics experiments and the stratification of patients for precision therapies.

Chronic Obstructive Pulmonary Disease Management and Outcomes publication trend

The graph below shows the total number of articles in chronic obstructive pulmonary disease management and outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Forced expiratory volume in 1 s (FEV1): The volume of air that can be forcibly exhaled in one second, a key measure of airflow limitation in COPD.

Exacerbation: An acute worsening of respiratory symptoms requiring additional therapy, often leading to hospitalisation and accelerated disease progression.

Genome-wide association study (GWAS): A research method that scans genetic variants across the genome to identify associations with traits or diseases such as COPD.

Radiomic nomogram: A statistical model combining quantitative imaging features with clinical factors to predict disease presence or outcomes.

Eosinophil: A type of white blood cell involved in inflammatory responses, implicated in specific COPD phenotypes and therapeutic targeting.

References

1. Eosinophils promote pulmonary matrix destruction and emphysema via Cathepsin L. Signal Transduction and Targeted Therapy (2023).
2. Multi-ancestry genome-wide association analyses improve resolution of genes and pathways influencing lung function and chronic obstructive pulmonary disease risk. Nature Genetics (2023).
3. CT whole lung radiomic nomogram: a potential biomarker for lung function evaluation and identification of COPD. Military Medical Research (2024).
4. Machine learning and deep learning predictive models for long-term prognosis in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. The Lancet Digital Health (2023).